A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

Journal article

Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months.

Authors: Dunachie, S; Walther, M; Vuola, J; Webster, D; Keating, S

• Publication status: Published
• Journal: Vaccine
• Volume: 24
• Issue: 15
• Pages: 2850-2859
• Publication date: 2006-04-01
• DOI: 10.1016/j.vaccine.2005.12.041
• EISSN: 1873-2518
• ISSN: 0264-410X
• Language: English
• Keywords: Vaccinia virus; Malaria Vaccines; T-Lymphocytes; Middle Aged; Adolescent; Immunization, Secondary; Humans; Malaria; Male; Female; Antibodies, Protozoan; Interferon-gamma; Adult